AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure We continue to believe AbbVie needs to expand its late-stage pipeline.

AbbVie’s focus on building a strong portfolio, particularly in immunology and neurology, further supports the Buy rating. The company’s plans to enhance its offering with promising trial ...

With a diversified portfolio in immunology, oncology, aesthetics, neuroscience, and eye care, AbbVie Inc has shown a resilient financial performance.

Less than a year ago, AbbVie's star immunology drug Rinvoq picked up its seventh FDA approval< | AbbVie's Rinvoq has racked up seven FDA approvals in recent years, and another expansion into giant ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The ...

AbbVie's impressive Q2 2024 financial results show surging sales in immunology and neuroscience. Read why I continue to cover ABBV stock with a 'Buy' rating.

All in all, I rated AbbVie a Buy based on its leadership in immunology, strategic expansion into oncology and neuroscience, and an undervalued stock.